🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome

Recruitingn/aAges 1 Day - 5 DaysAllMilton S. Hershey Medical Center
NCT05937594 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Infants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed study will define the molecular mechanisms that regulate the response to opioid withdrawal in the developing brain by focusing on three candidate microRNAs (let-7a, miR-146a, miR-192) that have been shown to respond to opioid exposure in animal models and adults, and are impacted in both my preliminary study of infants with NAS, and my human neural progenitor cell (NPC) design of opioid withdrawal. By determining the mechanism through which microRNAs impact NPC differentiation in opioid withdrawal, and determining whether exosomal salivary microRNA levels predict treatment dose and neurodevelopmental outcomes in inf

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Newborns ≥35weeks gestation with chronic in-utero opioid exposure (\>1month of gestation exposure). Maternal exposure will be determined by evaluating the medical records for maternal medication use, maternal urine toxicology and neonatal meconium toxicology results per standard clinical care * Neonates born at Penn State Hershey Medical Center or transferred at \<48 hours after birth * Mothers with chronic in-utero opioid use during pregnancy ( ≥1month of gestation) Exclusion Criteria: * \<35 week gestation * Infant required mechanical ventilation or non-invasive mechanical support * Infant exposure to magnesium sulfate * Opioid-exposed neonates who are actively receiving dextrose infusion for persistent neonatal hypoglycemia at the time of enrollment (\<48hours after birth). * Infant with major congenital anomalies * Parent or guardian unable to provide consent * Mothers and neonates without history of opioid exposure/dependence
💊

What it tests

  • Buccal swab saliva for further genetic testing
📍

Where

1 site
Penn State Milton S. Hershey Medical Center
Hershey, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy